Cconsensus is $260.78M. Maravai said the preliminary year-end results are subject to year-end closing adjustments.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences initiated with a Neutral at Guggenheim
- Maravai Lifesciences chairman Carl Hull to retire, R. Andrew Eckert to succeed
- Maravai LifeSciences Appoints New Chairman Amid Leadership Transition
- Maravai Lifesciences downgraded to Sell from Neutral at Goldman Sachs
- Maravai Lifesciences initiated with a Peer Perform at Wolfe Research